Search Results

There are 14197 results for: content related to: Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor

  1. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man

    Journal of Thrombosis and Haemostasis

    Volume 13, Issue 8, August 2015, Pages: 1494–1502, S. Nylander, F. Wågberg, M. Andersson, T. Skärby and D. Gustafsson

    Article first published online : 23 JUL 2015, DOI: 10.1111/jth.13027

  2. Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 1, January 2013, Pages: 35–41, M. Sjöstrand, H. Ericsson, M. Hartford, E. Norjavaara and J. W. Eriksson

    Article first published online : 9 SEP 2012, DOI: 10.1111/j.1463-1326.2012.01672.x

  3. You have free access to this content
    Antithrombotic phosphoinositide 3-kinase β inhibitors in humans: a ‘shear’ delight!

    Journal of Thrombosis and Haemostasis

    Volume 10, Issue 10, October 2012, Pages: 2123–2126, S. P. JACKSON and S. M. SCHOENWAELDER

    Article first published online : 1 OCT 2012, DOI: 10.1111/j.1538-7836.2012.04912.x

  4. You have free access to this content
    Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines

    International Journal of Cancer

    Volume 125, Issue 10, 15 November 2009, Pages: 2332–2341, Kathryn Balmanno, Simon D. Chell, Annette S. Gillings, Shaista Hayat and Simon J. Cook

    Article first published online : 28 MAY 2009, DOI: 10.1002/ijc.24604

  5. Discovery of Allosteric MEK Inhibitors

    Kinase Inhibitor Drugs

    Eli Wallace, James F. Blake, Pages: 229–252, 2009

    Published Online : 28 SEP 2009, DOI: 10.1002/9780470524961.ch9

  6. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer

    The Prostate

    Volume 75, Issue 15, November 1, 2015, Pages: 1747–1759, Hongzoo Park, Yunlim Kim, Jee-Won Sul, In Gab Jeong, Hye-Jin Yi, Jae Beom Ahn, Jong Soon Kang, Jieun Yun, Jung Jin Hwang and Choung-Soo Kim

    Article first published online : 7 AUG 2015, DOI: 10.1002/pros.23057

  7. You have free access to this content
    Blockade of MEK signaling potentiates 5-Aza-2′-deoxycytidine-induced apoptosis and upregulation of p21waf1 in acute myelogenous leukemia cells

    International Journal of Cancer

    Volume 125, Issue 5, 1 September 2009, Pages: 1168–1176, Chie Nishioka, Takayuki Ikezoe, Jing Yang, Naoki Komatsu, H. Phillip Koeffler and Akihito Yokoyama

    Article first published online : 18 FEB 2009, DOI: 10.1002/ijc.24377

  8. You have free access to this content
    Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma

    British Journal of Haematology

    Volume 139, Issue 1, October 2007, Pages: 55–63, Iris Breitkreutz, Marc S. Raab, Sonia Vallet, Teru Hideshima, Noopur Raje, Dharminder Chauhan, Nikhil C. Munshi, Paul G. Richardson and Kenneth C. Anderson

    Article first published online : 11 SEP 2007, DOI: 10.1111/j.1365-2141.2007.06747.x

  9. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program

    Pediatric Blood & Cancer

    Volume 55, Issue 4, October 2010, Pages: 668–677, E. Anders Kolb, Richard Gorlick, Peter J. Houghton, Christopher L. Morton, Geoffrey Neale, Stephen T. Keir, Hernan Carol, Richard Lock, Doris Phelps, Min H. Kang, C. Patrick Reynolds, John M. Maris, Catherine Billups and Malcolm A. Smith

    Article first published online : 24 MAY 2010, DOI: 10.1002/pbc.22576

  10. You have free access to this content
    AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma


    Volume 116, Issue 5, 1 March 2010, Pages: 1315–1325, Hung Huynh

    Article first published online : 25 JAN 2010, DOI: 10.1002/cncr.24863

  11. The effects of the nonselective benzodiazepine lorazepam and the α23 subunit-selective GABAA receptor modulators AZD7325 and AZD6280 on plasma prolactin levels

    Clinical Pharmacology in Drug Development

    Volume 4, Issue 2, March/April 2015, Pages: 149–154, Erik T. te Beek, Xia Chen, Gabriël E. Jacobs, Kimberly J. Nahon, Marieke L. de Kam, Jaakko Lappalainen, Alan J. Cross, Joop M. A. van Gerven and Justin L. Hay

    Article first published online : 27 AUG 2014, DOI: 10.1002/cpdd.134

  12. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach

    Molecular Carcinogenesis

    Volume 49, Issue 4, April 2010, Pages: 353–362, Young-Kwang Yoon, Hwang-Phill Kim, Sae-Won Han, Do Youn Oh, Seock-Ah Im, Yung-Jue Bang and Tae-You Kim

    Article first published online : 26 MAR 2010, DOI: 10.1002/mc.20607

  13. Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma

    Veterinary and Comparative Oncology

    Volume 13, Issue 3, September 2015, Pages: 288–304, J. S. Fowles, C. L. Denton and D. L. Gustafson

    Article first published online : 7 JUN 2013, DOI: 10.1111/vco.12044

  14. MiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting Bim

    Cell Biology International

    Volume 38, Issue 4, April 2014, Pages: 435–443, Xiao-Bin Lv, Xing Zhang, Lan Deng, Ling Jiang, Wei Meng, Zhigang Lu and Xiuju Wang

    Article first published online : 12 FEB 2014, DOI: 10.1002/cbin.10225

  15. Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial

    International Journal of Clinical Practice

    Volume 63, Issue 4, April 2009, Pages: 667–670, S. Husted, R. A. Harrington, C. P. Cannon, R. F. Storey, P. Mitchell and H. Emanuelsson

    Article first published online : 16 MAR 2009, DOI: 10.1111/j.1742-1241.2009.02030.x

  16. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma

    Pigment Cell & Melanoma Research

    Volume 27, Issue 6, November 2014, Pages: 1154–1158, Vito W. Rebecca, Gretchen M. Alicea, Kim H. T. Paraiso, Harshani Lawrence, Geoffrey T. Gibney and Keiran S. M. Smalley

    Article first published online : 1 SEP 2014, DOI: 10.1111/pcmr.12303

  17. Ketamine and other glutamate receptor modulators for depression in adults

    Intervention Review

    The Cochrane Library

    Caroline Caddy, Ben H Amit, Tayla L McCloud, Jennifer M Rendell, Toshi A Furukawa, Rupert McShane, Keith Hawton and Andrea Cipriani

    Published Online : 23 SEP 2015, DOI: 10.1002/14651858.CD011612.pub2

  18. Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 12, December 2012, Pages: 1114–1122, L. A. Morrow, M. Leonsson-Zachrisson, H. Ericsson, M. Wollbratt, M. Knutsson, M. Hompesch and E. Norjavaara

    Article first published online : 31 JUL 2012, DOI: 10.1111/j.1463-1326.2012.01661.x

  19. AZD6140 and bleeding: towards safer antiplatelet therapy?

    International Journal of Clinical Practice

    Volume 63, Issue 4, April 2009, Pages: 537–539, A. Siddique, E. Shantsila and G. Y. H. Lip

    Article first published online : 16 MAR 2009, DOI: 10.1111/j.1742-1241.2008.01963.x

  20. You have free access to this content
    Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes

    British Journal of Pharmacology

    Volume 171, Issue 7, April 2014, Pages: 1629–1641, D J Baker, A M Atkinson, G P Wilkinson, G J Coope, A D Charles and B Leighton

    Article first published online : 18 MAR 2014, DOI: 10.1111/bph.12498